

**SUPPLEMENT DATED 18<sup>th</sup> NOVEMBER, 2022 TO  
THE PROSPECTUS DATED 7<sup>th</sup> SEPTEMBER, 2022**



**GSK plc**

*(incorporated in England and Wales with limited liability under registered number 3888792)*

**GlaxoSmithKline Capital plc**

*(incorporated in England and Wales with limited liability under registered number 2258699)*

**GSK Capital K.K.**

*(incorporated with limited liability in Japan under registered number 0110-01-117664)*

**GSK Capital B.V.**

*(incorporated with limited liability in the Netherlands under registered number 81761198)*

**£20,000,000,000**

**Euro Medium Term Note Programme**

**unconditionally and irrevocably guaranteed in the case of Notes issued by**

**GlaxoSmithKline Capital plc, GSK Capital K.K. and GSK Capital B.V. by**

**GSK plc**

*(incorporated in England and Wales with limited liability under registered number 3888792)*

This supplement (the "**Supplement**", which definition shall also include all information incorporated by reference herein) to the base prospectus dated 7<sup>th</sup> September, 2022, as supplemented by a supplementary prospectus dated 3<sup>rd</sup> November, 2022 (such base prospectus as so supplemented, the "**Prospectus**", which definition includes all information incorporated by reference therein) constitutes a supplementary prospectus for the purposes of Article 23 of Regulation (EU) 2017/1129 as it forms part of domestic law of the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 (the "**UK Prospectus Regulation**") and is prepared in connection with the £20,000,000,000 Euro Medium Term Note Programme (the "**Programme**") of GSK plc, GlaxoSmithKline Capital plc ("**GSK Capital plc**"), GSK Capital K.K. ("**GSK Capital K.K.**") and GSK Capital B.V. ("**GSK Capital B.V.**" and, together with GSK plc, GSK Capital plc and GSK Capital K.K., the "**Issuers**" and each an "**Issuer**"). The payment of all amounts owing in respect of Notes issued under the Programme by GSK Capital plc, GSK Capital K.K. and GSK Capital B.V. will be unconditionally and irrevocably guaranteed by GSK plc (the "**Guarantor**").

Terms defined in the Prospectus have the same meaning when used in this Supplement.

This Supplement has been approved by the United Kingdom's Financial Conduct Authority (the "**FCA**"), in its capacity as competent authority for the purposes of the UK Prospectus Regulation, as a supplement to the Prospectus. This Supplement together with the Prospectus comprises a base prospectus for the purposes of Article 8 of the UK Prospectus Regulation.

Each Issuer and the Guarantor accepts responsibility for the information contained in this Supplement. To the best of the knowledge and belief of each Issuer and the Guarantor the information contained in this Supplement is in accordance with the facts and this Supplement does not omit anything likely to affect the import of such information. No other person has authorised or is responsible for the whole or any part of this Supplement or has any liability with respect to it.

This Supplement is supplemental to, updates, must be read in conjunction with, and forms part of, the Prospectus and any other supplements to the Prospectus issued by the Issuers and the Guarantor.

Other than in relation to the documents which are deemed to be incorporated by reference, the information on the websites to which this Supplement refers does not form part of this Supplement and has not been scrutinised or approved by the FCA.

The purpose of this Supplement is to incorporate by reference: (A) the Group's press releases dated (i) 7th November, 2022 announcing an update on the DREAMM-3 phase III trial for Blenrep in relapsed/refractory multiple myeloma (the "**Blenrep Press Release**"), (ii) 10th November, 2022 announcing the European Commission approval of Sanofi and GSK's next generation COVID-19 booster vaccine VidPrevtyl Beta (the "**VidPrevtyl Beta Press Release**"), and (iii) 11th November, 2022 announcing an update on Zejula (niraparib) US prescribing information (the "**Zejula (niraparib) Press Release**" and together with the Blenrep Press Release and the VidPrevtyl Beta Press Release, the "**Press Releases**"); and (B) GlaxoSmithKline Capital PLC's RNS announcement in relation to the final results of the Tender Offer launched on 8th November, 2022 (the "**Tender Offer Final Results Announcement**").

### ***Documents Incorporated by Reference***

The Blenrep Press Release (which can be accessed from the following hyperlink <https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/>), the VidPrevtyl Beta Press Release (which can be accessed from the following hyperlink <https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-s-next-generation-covid-19-booster-vaccine-vidprevtyl-beta-approved-by-ec/>), the Zejula (niraparib) Press Release (which can be accessed from the following hyperlink <https://www.gsk.com/en-gb/media/press-releases/gsk-provides-an-update-on-zejula-niraparib-us-prescribing-information/>) and the Tender Offer Final Results Announcement (which can be accessed from the following hyperlink <https://otp.tools.investis.com/clients/uk/gsk/rns/regulatory-story.aspx?cid=410&newsid=1644705>), which have all been previously published, or are published simultaneously with this Supplement and have been filed with the FCA, shall be deemed to be incorporated in, and to form part of, this Supplement and, by virtue of this Supplement, shall be deemed to be incorporated in, and to form part of, the Prospectus.

Any documents themselves incorporated by reference in the Press Releases or the Tender Offer Final Results Announcement shall not form part of this Supplement.

Copies of this Supplement, the Press Releases and the Tender Offer Final Results Announcement, incorporated by reference herein have been filed with the National Storage Mechanism operated by the FCA, and are available for viewing at <https://data.fca.org.uk/#/nsm/nationalstoragemechanism>.

To the extent there is any inconsistency between (a) any statement in this Supplement or any statement incorporated by reference into the Prospectus by this Supplement and (b) any other statement in, or incorporated by reference in, the Prospectus prior to the date of this Supplement, the statements in (a) above will prevail.

Save as disclosed in this Supplement and the Prospectus, neither the Issuers nor the Guarantor is aware of any other significant new factor, material mistake or material inaccuracy relating to information included in the Prospectus which is capable of affecting an informed assessment by investors of Notes issued under the Programme since the publication of the Prospectus.